Current therapies in Hodgkin's disease

被引：15

作者：

Kogel, K. E. ^{[1
]}

Sweetenham, J. W. ^{[1
]}

机构：

[1] Univ Colorado, Hlth Sci Ctr, Div Med Oncol, Denver, CO 80262 USA

来源：

EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING | 2003年 / 30卷 / Suppl 1期

关键词：

Hodgkin's disease; treatment; early-stage disease; long-term toxicity;

D O I：

10.1007/s00259-003-1156-7

中图分类号：

R8 [特种医学]; R445 [影像诊断学];

学科分类号：

1002 ; 100207 ; 1009 ;

摘要：

Advances in the treatment of Hodgkin's disease (HD) have resulted in cure rates of greater than 80%. This remarkable achievement has occurred in the past 50 years secondary to improvements in combination chemotherapy and radiotherapy. Over the last several decades, with the increase in long-term survivors of HD, it has become evident that cure is not the only issue, and late side-effects of treatment, including secondary malignancies and impaired fertility, are of major concern as well. As a result, attempts to improve response and survival rates by intensifying therapy must be countered against the potential for long-term toxicity.

引用

页码：S19 / S27

页数：9

共 57 条

[1] Long-term results of blood and marrow transplantation for Hodgkin's lymphoma [J].

Akpek, G ;

Ambinder, RF ;

Piantadosi, S ;

Abrams, RA ;

Brodsky, RA ;

Vogelsang, GB ;

Zahurak, ML ;

Fuller, D ;

Miller, CB ;

Noga, SJ ;

Fuchs, E ;

Flinn, IW ;

O'Donnell, P ;

Seifter, EJ ;

Mann, RB ;

Jones, RJ .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (23) :4314-4321

[2] ALLOGENEIC, SYNGENEIC, AND AUTOLOGOUS MARROW TRANSPLANTATION FOR HODGKINS-DISEASE - THE 21-YEAR SEATTLE EXPERIENCE [J].

ANDERSON, JE ;

LITZOW, MR ;

APPELBAUM, FR ;

SCHOCH, G ;

FISHER, LD ;

BUCKNER, CD ;

PETERSEN, FB ;

CRAWFORD, SW ;

PRESS, OW ;

SANDERS, JE ;

BENSINGER, WI ;

MARTIN, PJ ;

STORB, R ;

SULLIVAN, KM ;

HANSEN, JA ;

THOMAS, ED .

JOURNAL OF CLINICAL ONCOLOGY, 1993, 11 (12) :2342-2350

[3]

ANDERSON JR, 1995, ANN ONCOL, V6, P167

[4]

[Anonymous], ANN ONCOLOGY S2

[5] BRIEF CHEMOTHERAPY, STANFORD-V, AND ADJUVANT RADIOTHERAPY FOR BULKY OR ADVANCED-STAGE HODGKINS-DISEASE - A PRELIMINARY-REPORT [J].

BARTLETT, NL ;

ROSENBERG, SA ;

HOPPE, RT ;

HANCOCK, SL ;

HORNING, SJ .

JOURNAL OF CLINICAL ONCOLOGY, 1995, 13 (05) :1080-1088

[6] EXTENDED-FIELD RADIOTHERAPY IS SUPERIOR TO MOPP CHEMOTHERAPY FOR THE TREATMENT OF PATHOLOGICAL STAGE-I-IIA HODGKINS-DISEASE - 8-YEAR UPDATE OF AN ITALIAN PROSPECTIVE RANDOMIZED STUDY [J].

BITI, GP ;

CIMINO, G ;

CARTONI, C ;

MAGRINI, SM ;

ANSELMO, AP ;

ENRICI, RM ;

BELLESI, GP ;

BOSI, A ;

PAPA, G ;

GIANNARELLI, D ;

PONTICELLI, P ;

PAPI, MG ;

FERRINI, PLR ;

BIAGINI, C ;

MANDELLI, F .

JOURNAL OF CLINICAL ONCOLOGY, 1992, 10 (03) :378-382

[7] ALTERNATING NON-CROSS-RESISTANT COMBINATION CHEMOTHERAPY OR MOPP IN STAGE-IV HODGKINS-DISEASE - A REPORT OF 8-YEAR RESULTS [J].

BONADONNA, G ;

VALAGUSSA, P ;

SANTORO, A .

ANNALS OF INTERNAL MEDICINE, 1986, 104 (06) :739-746

[8]

BONFANTE V, 2001, P AN M AM SOC CLIN, V20, pA281

[9] Phase 1 trial of the novel bispecific molecule H22xKi-4 in patients with refractory Hodgkin lymphoma [J].

Borchmann, P ;

Schnell, R ;

Fuss, I ;

Manzke, O ;

Davis, T ;

Lewis, LD ;

Behnke, D ;

Wickenhauser, C ;

Schiller, P ;

Diehl, V ;

Engert, A .

BLOOD, 2002, 100 (09) :3101-3107

[10] CHEMOTHERAPY OF ADVANCED HODGKINS-DISEASE WITH MOPP, ABVD, OR MOPP ALTERNATING WITH ABVD [J].

CANELLOS, GP ;

ANDERSON, JR ;

PROPERT, KJ ;

NISSEN, N ;

COOPER, MR ;

HENDERSON, ES ;

GREEN, MR ;

GOTTLIEB, A ;

PETERSON, BA .

NEW ENGLAND JOURNAL OF MEDICINE, 1992, 327 (21) :1478-1484

← 1 2 3 4 5 6 →